Jennifer B Pierson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6965396/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress. Journal of Pharmacological and Toxicological Methods, 2016, 81, 15-20.	0.7	335
2	International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment. Cell Reports, 2018, 24, 3582-3592.	6.4	254
3	Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study. Toxicological Sciences, 2018, 164, 550-562.	3.1	90
4	Can nonâ€clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium. British Journal of Pharmacology, 2018, 175, 606-617.	5.4	44
5	Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes. Frontiers in Pharmacology, 2019, 10, 934.	3.5	30
6	Non-Lethal Endotoxin Injection: A Rat Model of Hypercoagulability. PLoS ONE, 2017, 12, e0169976.	2.5	28
7	Electrophysiological characterization of drug response in hSC-derived cardiomyocytes using voltage-sensitive optical platforms. Journal of Pharmacological and Toxicological Methods, 2019, 99, 106612.	0.7	26
8	A public–private consortium advances cardiac safety evaluation: Achievements of the HESI Cardiac Safety Technical Committee. Journal of Pharmacological and Toxicological Methods, 2013, 68, 7-12.	0.7	25
9	Assessing Drug-Induced Long QT and Proarrhythmic Risk Using Human Stem-Cell-Derived Cardiomyocytes in a Ca2+ Imaging Assay: Evaluation of 28 CiPA Compounds at Three Test Sites. Toxicological Sciences, 2019, 170, 345-356.	3.1	21
10	Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms. Frontiers in Pharmacology, 2019, 10, 884.	3.5	20
11	The Challenges of Predicting Drug-Induced QTc Prolongation in Humans. Toxicological Sciences, 2022, 187, 3-24.	3.1	13
12	A Proof-of-Concept Evaluation of JTPc and Tp-Tec as Proarrhythmia Biomarkers in Preclinical Species: A Retrospective Analysis by an HESI-Sponsored Consortium. International Journal of Toxicology, 2019, 38, 23-32.	1.2	12
13	Can We Panelize Seizure?. Toxicological Sciences, 2021, 179, 3-13.	3.1	9
14	Use of the ZDF rat to model dietary fat induced hypercoagulability is limited by progressive and fatal nephropathy. Journal of Pharmacological and Toxicological Methods, 2021, 107, 106933.	0.7	6
15	Echocardiographic and hemodynamic indices of myocardial contractility simultaneously evaluated in telemetered beagle dogs: A HESI-sponsored cross-company evaluation. Journal of Pharmacological and Toxicological Methods, 2020, 105, 106897	0.7	1